<div id="readability-page-1"><p>In a report released yesterday, Lee Hambright from Bernstein maintained a Buy rating on Dexcom, with a price target of <span id="expert-recommendation-target">$84.00</span>. The company’s shares closed yesterday at $66.96.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>Hambright covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Insulet, and Medtronic. According to TipRanks, Hambright has an average return of <span>6.9%</span> and a 61.18% success rate on recommended stocks. </p> <p>Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $85.75, which is a 28.06% upside from current levels. In a report released yesterday, Citi also maintained a Buy rating on the stock with a $77.00 price target.</p></div>

DXCM

<p>Bernstein's Lee Hambright maintains a Buy rating on Dexcom with a price target of $84.00, while the stock closed at $66.96. The analyst consensus is a Strong Buy with an average price target of $85.75, indicating a 28.06% upside. Citi also maintains a Buy rating with a $77.00 target. Hambright has a 6.9% average return and a 61.18% success rate on stocks.</p>

Bernstein Remains a Buy on Dexcom (DXCM)